London NW3 2QG SYNOPSIS The in vitro activities of metronidazole, nimorazole, and tinidazole were compared against 69 strains of obligately anaerobic Gram-negative bacilli. Geometric mean MICs were 0 34, 1 05, and 0-28 Hg/ml respectively. Thirty-six strains were also tested by the disk method. Correlation between MIC and diameter of the zones of inhibition was poor.
Metronidazole
(1-,B-hydroxymethyl-2-methyl-5-nitroimidazole, Flagyl, May & Baker) is at present the drug used most widely for the treatment of Trichomonas vaginalis infection. It is of interest that it has also been effective in the treatment of acute ulcerative gingivitis (Shinn, 1962; Davies et al, 1964; Shinn et al, 1965) , an infection in which anaerobic bacteria (Treponema vincentii and Fusobacterium spp.) are believed to have an aetiological r6le. Recent studies have shown that all the clinically important species of anaerobic bacteria are sensitive to therapeutically attainable concentrations of metronidazole Csukas, 1969a, b, c, 1970; Prince et al, 1969; Ueno et al, 1971; Videau, 1971; Nastro and Finegold, 1972; Tally et al, 1972 Tally et al, , 1974 Finegold and Sutter, 1972; Whelan and Hale, 1973; Mitchell, 1973; Washington et al, 1974; Dornbusch and Nord, 1974; Phillips, 1974; Staneck and Washington, 1974) . In addition, metronidazole is consistently bactericidal in action, which is a property not shown by clindamycin, rifampicin or chloramphenicol (Nastro and Finegold, 1972; Finegold and Sutter, 1972; Whelan and Hale, 1973) . Two reports have appeared on the clinical use of metronidazole: Tally et al (1972) successfully treated three patients with infections caused by Gramnegative anaerobic bacteria, and the Study Group (1974) showed that metronidazole was effective both therapeutically and prophylactically in gynaecological patients with pelvic sepsis. Nimorazole1 (1-(N-P-ethylmorpholino)-5-nitro-"Previously known as nitrinidazine.
Received for publication 14 April 1975. imidazole, Nagoxin, Carlo Erba) and tinidazole (1 (2-ethylsulphonylethyl)-2-methyl-5-nitroimidazole Fasigyn, Pfizer) are also 5-nitroimidazoles whose antitrichomonal activity in vitro is similar to that of metronidazole Howes et al, 1970) . Both have been used successfully to treat trichomoniasis, with reduction in both daily doses and treatment period compared with metronidazole (Rognoni and Sideri, 1969; Gyorik and Wenner, 1971) . Nimorazole was also found to be as effective as metronidazole in the treatment of acute ulcerative gingivitis (Lozdan et al, 1971) . Considering the superior pharmacokinetic properties of nimorazole and tinidazole, we thought it worthwhile to carry out a comparison of the in vitro activity of these three 5-nitroimidazoles against Gram-negative anaerobic bacteria. 43 of these as B. fragilis, since they were resistant to polymyxin B (10 ,ug/ml), kanamycin (2 mg/ml), and benzylpenicillin (2 u/ml) (Finegold et al, 1967) . The other two strains were sensitive to benzylpenicillin and thus were classified as Bacteroides spp.
Methods and Materials

5-NITROIMIDAZOLES
MIC DETERMINATION
Throughout these experiments, media were supplemented with yeast extract (1 %), haemin (5 ,ug/ml), and menadione (0 5 ,ug/ml).
Serial doubling dilutions of the drugs were made in brain heart infusion agar (Oxoid, CM 375) containing 5 % lysed, defibrinated horse blood. Bacteria were grown in 10 ml amounts of thioglycollate broth (Baltimore Biological Laboratories, no. 135C) incubated anaerobically at 37°C for 22 hr, using the GasPak system. Such cultures were diluted 1:500 in sterile 0-06 M sodium phosphate buffer containing 0 3 g/l cysteine hydrochloride, and inoculated on to the agar with a multiple inoculating device (see Reynolds et al, 1974 
Discussion
A large number of reports over the past few years have shown metronidazole to be highly active against both Gram-positive and Gram-negative anaerobic bacteria (for review see Hamilton-Miller, 1975) . Two other nitroimidazoles, nimorazole and tinidazole, are currently available for the treatment of trichomoniasis (although tinidazole is not at present available on prescription in the UK.) We have not seen any reports on the antibacterial activity of nimorazole, and only two concerning tinidazole. Edwards et al (1973) reported that tinidazole was slightly less active than metronidazole against eight strains of Clostridium spp, a conclusion confirmed by Dornbusch and Nord (1974) , who also found tinidazole to be more active than metronidazole against Gram-negative organisms. Our results have been extended to include nimorazole but in terms of metronidazole and tinidazole they agree very closely with those of Dornbusch and Nord (1974) . Summation of published data available on the activity of metronidazole against anaerobic bacteria shows that 1052 out of 1071 strains were sensitive (taking the break-point as being either 12-5 or 16 ,ug/ml).
Poor correlation was found in the disk test between zone size and sensitivity. However, since all the strains tested here may be regarded as sensitive, criteria allowing precise interpretation cannot be stated. We suggest an MIC of 16 ,ug/ml as the breakpoint, since this value should be obtainable systemically after a 1 g dose of any of these three compounds. If this value is accepted, strains giving a zone size greater than 13 mm for metronidazole, 7 mm for nimorazole, and 15 mm for tinidazole can be considered as sensitive.
Three groups of compounds containing a primary nitro group among other features have now been shown to possess good activity against anaerobic bacteria, chloramphenicol, nitroimidazoles, and nitrofurans. The possession of such a group may be the determining factor in such activity, and it will be of interest to test this hypothesis with further compounds.
The nitroimidazoles are at present available only as oral preparations, which may be a disadvantage if the treatment of critically ill patients is contemplated. In view of the fact that metronidazole has been used successfully on a small scale for the treatment of systemic bacterial infections, the superior pharmacokinetics (Welling and Monro, 1972; de Carneri, 1969) of the two other related compounds allied to their equivalent antimicrobial activity make clinical studies of tinidazole and nimorazole mandatory. 
